NASDAQ:HRTX Heron Therapeutics (HRTX) Stock Price, News & Analysis $3.02 +0.15 (+5.23%) (As of 10:08 AM ET) Add Compare Share Share Today's Range$2.87▼$3.1250-Day Range$2.32▼$3.8652-Week Range$0.50▼$3.93Volume323,602 shsAverage Volume2.64 million shsMarket Capitalization$454.96 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Heron Therapeutics alerts: Email Address Heron Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside109.1% Upside$6.00 Price TargetShort InterestBearish20.23% of Shares Sold ShortDividend StrengthN/ASustainability-1.96Upright™ Environmental ScoreNews Sentiment0.71Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.10) to $0.01 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.40 out of 5 starsMedical Sector251st out of 879 stocksPharmaceutical Preparations Industry113th out of 417 stocks 3.5 Analyst's Opinion Consensus RatingHeron Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageHeron Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Heron Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted20.23% of the outstanding shares of Heron Therapeutics have been sold short.Short Interest Ratio / Days to CoverHeron Therapeutics has a short interest ratio ("days to cover") of 14.5, which indicates bearish sentiment.Change versus previous monthShort interest in Heron Therapeutics has recently increased by 1.43%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldHeron Therapeutics does not currently pay a dividend.Dividend GrowthHeron Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHeron Therapeutics has received a 61.27% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Antiemetics and antinauseants (A04)", "Bupivacaine", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Heron Therapeutics is -1.96. Previous Next 2.1 News and Social Media Coverage News SentimentHeron Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Heron Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for HRTX on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Heron Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Heron Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.40% of the stock of Heron Therapeutics is held by insiders.Percentage Held by Institutions80.01% of the stock of Heron Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Heron Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Heron Therapeutics are expected to grow in the coming year, from ($0.10) to $0.01 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Heron Therapeutics is -4.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Heron Therapeutics is -4.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Heron Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...Get your free information kit NOW, before it's too late. About Heron Therapeutics Stock (NASDAQ:HRTX)Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Read More HRTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HRTX Stock News HeadlinesJuly 5 at 1:38 AM | americanbankingnews.comEquities Analysts Set Expectations for Heron Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:HRTX)July 4, 2024 | americanbankingnews.comHeron Therapeutics (NASDAQ:HRTX) Shares Down 2.9% July 8, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.July 4, 2024 | americanbankingnews.comTraders Buy High Volume of Put Options on Heron Therapeutics (NASDAQ:HRTX)July 4, 2024 | americanbankingnews.comInvestors Buy Large Volume of Heron Therapeutics Put Options (NASDAQ:HRTX)July 2, 2024 | prnewswire.comHeron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")June 27, 2024 | seekingalpha.comHeron Therapeutics: Opioid-Free Surgical Pain Relief Maven With Low Cash ReservesMay 29, 2024 | finanznachrichten.deHeron Therapeutics, Inc.: Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF Vial Access Needle ("VAN")July 8, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.May 29, 2024 | baystreet.caHeron Dips on Progress Re: ZynreliefMay 29, 2024 | markets.businessinsider.comHeron Therapeutics Submits Prior Approval Supplement To FDA For Zynrelef VANMay 29, 2024 | finance.yahoo.comPleasing Signs As A Number Of Insiders Buy Heron Therapeutics StockMay 29, 2024 | prnewswire.comHeron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")May 9, 2024 | finance.yahoo.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Just Released Its First-Quarter Earnings: Here's What Analysts ThinkMay 8, 2024 | finance.yahoo.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comHeron Therapeutics Inc (HRTX) Q1 2024 Earnings Call Transcript Highlights: Significant ...May 8, 2024 | finance.yahoo.comHeron Therapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 7, 2024 | seekingalpha.comHeron Therapeutics, Inc. 2024 Q1 - Results - Earnings Call PresentationSee More Headlines Receive HRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/08/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HRTX CUSIPN/A CIK818033 Webwww.herontx.com Phone(858) 251-4400Fax650-365-6490Employees126Year Founded1983Price Target and Rating Average Stock Price Target$6.00 High Stock Price Target$7.00 Low Stock Price Target$5.00 Potential Upside/Downside+109.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-110,560,000.00 Net Margins-61.28% Pretax Margin-61.28% Return on EquityN/A Return on Assets-37.18% Debt Debt-to-Equity RatioN/A Current Ratio2.47 Quick Ratio1.90 Sales & Book Value Annual Sales$127.04 million Price / Sales3.40 Cash FlowN/A Price / Cash FlowN/A Book Value($0.23) per share Price / Book-12.48Miscellaneous Outstanding Shares150,650,000Free Float141,011,000Market Cap$432.37 million OptionableOptionable Beta1.80 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Craig Alexander Collard (Age 58)CEO & Director Ms. Ira Duarte (Age 55)Executive VP & CFO Mr. Ryan CraigVice President of MarketingMr. Sean T. Ristine (Age 54)Senior Vice President of Human Resources Mr. Robert Sullivan (Age 46)Senior VP of Oncology Care Franchise & Commercial Operations Dr. William P. Forbes Pharm. D. (Age 62)Pharm.D., Executive VP & Chief Development Officer Jeff CohnExecutive Director, Assistant General Counsel & Assistant SecretaryMore ExecutivesKey CompetitorsRevance TherapeuticsNASDAQ:RVNCMersana TherapeuticsNASDAQ:MRSNStoke TherapeuticsNASDAQ:STOKGeneration BioNASDAQ:GBIONGM BiopharmaceuticalsNASDAQ:NGMView All CompetitorsInsiders & InstitutionsCalifornia State Teachers Retirement SystemSold 6,634 shares on 5/16/2024Ownership: 0.007%Price T Rowe Associates Inc. MDBought 3,991 shares on 5/15/2024Ownership: 0.020%CM Management LLCSold 25,000 shares on 5/14/2024Ownership: 0.199%Vanguard Group Inc.Sold 224,196 shares on 5/10/2024Ownership: 5.387%State Board of Administration of Florida Retirement SystemBought 13,811 shares on 5/9/2024Ownership: 0.027%View All Insider TransactionsView All Institutional Transactions HRTX Stock Analysis - Frequently Asked Questions How have HRTX shares performed this year? Heron Therapeutics' stock was trading at $1.70 at the beginning of 2024. Since then, HRTX shares have increased by 68.8% and is now trading at $2.87. View the best growth stocks for 2024 here. How were Heron Therapeutics' earnings last quarter? Heron Therapeutics, Inc. (NASDAQ:HRTX) announced its quarterly earnings results on Tuesday, May, 7th. The biotechnology company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.06. The biotechnology company had revenue of $34.67 million for the quarter, compared to analyst estimates of $32.50 million. Does Heron Therapeutics have any subsidiaries? The following companies are subsidiaries of Heron Therapeutics: Heron Therapeutics B.V.. How do I buy shares of Heron Therapeutics? Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Heron Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Heron Therapeutics investors own include Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Editas Medicine (EDIT) and Immunomedics (IMMU). This page (NASDAQ:HRTX) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...Chaikin Analytics | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | SponsoredTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house...Wealthpin Pro | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
